Navigation Links
Researchers learn how signaling molecule orchestrates breast cancer's spread
Date:4/3/2008

NEW YORK, April 3, 2008 -- A study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) has uncovered how breast tumors use a particular type of molecule to promote metastasis -- the spread of cancer cells. Metastasis is the cause of approximately 90 percent of all cancer-related deaths. The study is published in the April 4, 2008, issue of Cell.

The work examines how cells in the body communicate with each other through cytokines, signaling molecules that direct a wide range of activities such as cell growth and movement. One important cytokine -- transforming growth factor -a (TGF-a) -- normally suppresses tumor development. However, according to the findings, cancer cells in humans are able to misuse these cytokines for their own gain by compelling TGF-a to enhance a tumor's ability to spread instead of suppressing it.

Using computer-based analysis to classify patient tumor samples based on their levels of TGF-a, the researchers observed that about half of all breast tumors contained active TGF-a. The affected tumors were found to be more aggressive and more likely to metastasize to the lung during the course of the patients' disease.

Using mice for their next set of experiments, the researchers discovered that TGF-a prompts breast cancer cells to make a second cytokine, known as angiopoietin-like 4 (ANGPTL4), which enhances the ability of the cancer to spread to the lungs through the blood circulation. The results show that the breast cancer cells use ANGPTL4 to break down the thin capillaries of the lung, thus facilitating their escape into the lung tissue.

"Our work shows that TGF-a enhances human breast cancer metastasis and reveals how tumor cells learn to exploit cytokines by making them work as a relay system to promote the spread of breast cancer," said the study's senior author, Joan Massagu, PhD, Chairman of the Cancer Biology and Genetics Program at MSKCC and a Howard Hughes Medical Institute investigator.

The researchers are now seeking to determine whether TGF-a and ANGPTL4 may also be active in other types of tumors, and are evaluating ways to interfere with the action of these cytokines to prevent metastasis in cancer patients.

"Deciphering how cancer cells take advantage of these cytokines is essential for developing therapies that can prevent this process," said the study's lead author David Padua, a graduate student in Dr. Massagu's lab. "Because cytokines act outside of cells they can be more easily targeted by drugs that block their activity."

The study provides support for developing agents to interfere with TGF-a in order to prevent and treat cancer metastasis. It points at ANGPTL4 as a possible target to interrupt the TGF-a stimulus of metastasis without interfering with the molecule's beneficial effects. Several pharmaceutical companies are currently testing TGF-a-blocking compounds in clinical trials as candidate drugs against breast cancer, melanoma, and other types of cancer.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... “Life Under Blankets”: an entrancing story about one ... Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her bachelor’s ... went on to pursue a master’s degree in education in the field of curriculum ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
(Date:1/22/2017)... FL (PRWEB) , ... January 22, 2017 , ... Zifam ... customers across the world, recently met with big-name retail buyers at the January ECRM ... evidence of efficacy and uses the utmost safety standards in all of its creations ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan 23, 2017 NeuroVive Pharmaceutical AB ... signed a preclinical collaboration agreement with the Children,s Hospital of ... Falk , M.D., a US key opinion leader in the ... ... evaluate compounds from NeuroVive,s research program, NVP015, in certain experimental ...
Breaking Medicine Technology: